Hypotensive effect of juxtascleral administration of anecortave acetate in different types of glaucoma

Journal of Glaucoma

Volumn 19, Issue 7, 2010, Pages 488-492

  Prata, Tiago Santos ^a   Tavares, Ivan Maynart ^a   Mello, Paulo Augusto ^a   Tamura, Caroline ^a   Lima, Verônica Castro ^a   Belfort, Rubens ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

anecortave acetate; glaucoma; intraocular pressure

Indexed keywords

ANECORTAVE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; TOPICAL ANESTHESIA; UVEITIS;

AGED; ANTERIOR EYE SEGMENT; DELAYED-ACTION PREPARATIONS; FEMALE; GLAUCOMA, ANGLE-CLOSURE; GLAUCOMA, OPEN-ANGLE; GLUCOCORTICOIDS; HUMANS; INJECTIONS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PREGNADIENEDIOLS; PROSPECTIVE STUDIES; SCLERA; TONOMETRY, OCULAR; VISUAL ACUITY;

EID: 77957603812     PISSN: 10570829     EISSN: None     Source Type: Journal    
DOI: 10.1097/IJG.0b013e3181c4b0e8     Document Type: Article

References (22)

1. Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120:701-713.
2. Collaborative Normal-Tension Glaucoma Study Group. The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Am J Ophthalmol. 1998;126:498-505.
3. Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol. 1998;126:487-497.
4. Heijl A, Leske MC, Bengtsson B, et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002;120:1268-1279.
5. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262-267.
6. Dasgupta S, Oates V, Bookhart BK, et al. Population-based persistency rates for topical glaucoma medications measured with pharmacy claims data. Am J Manag Care. 2002;8(10 suppl):S255-S261.
7. Fiscella RG. Persistency with glaucoma medication. Am J Ophthalmol. 2004;138:1093-1094.
8. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with topical ocular hypotensive therapy in a managed care population. Am J Ophthalmol. 2004;137(1 suppl):S3-S12.
9. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with pharmacotherapy in the management of glaucoma. Eur J Ophthalmol. 2003;13(suppl 4):S44-S52.
10. Reardon G, Schwartz GF, Mozaffari E. Patient persistency with ocular prostaglandin therapy: a population-based, retrospective study. Clin Ther. 2003;25:1172-1185.
11. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004;137(1 suppl):S13-S16.
12. Shaya FT, Mullins CD, Wong W, et al. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care. 2002;8(10 suppl):S271-S277.
13. Zhou Z, Althin R, Sforzolini BS, et al. Persistency and treatment failure in newly diagnosed open angle glaucoma patients in the United Kingdom. Br J Ophthalmol. 2004;88:1391-1394.
14. Clark AF. AL-3789: a novel ophthalmic angiostatic steroid. Expert Opin Investig Drugs. 1997;6:1867-1877.
15. McNatt LG, Weimer L, Yanni J, et al. Angiostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. J Ocul Pharmacol Ther. 1999;15:413-423.
16. D'Amico DJ, Goldberg MF, Hudson H, et al, Anecortave Acetate Clinical Study Group. Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in agerelated macular degeneration: twelve-month clinical outcomes. Ophthalmology. 2003;110:2372-2383.
17. Schmidt-Erfurth U, Michels S, Michels R, et al. Anecortave acetate for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration. Eur J Ophthalmol. 2005;15:482-485.
18. Klais CM, Eandi CM, Ober MD, et al. Anecortave acetate treatment for retinal angiomatous proliferation: a pilot study. Retina. 2006;26:773-779.
19. Hayek S, Scherrer M, Barthelmes D, et al. First clinical experience with anecortave acetate (Retaane). Klin Monatsbl Augenheilkd. 2007;224:279-281.
20. Clark AF. Mechanism of action of the angiostatic cortisene anecortave acetate. Surv Ophthalmol. 2007;52(suppl 1):S26-S34.
21. Robin AL, Clark AF, Covert DW, et al. Anterior juxtascleral delivery of anecortave acetate in eyes with primary open-angle glaucoma: a pilot investigation. Am J Ophthalmol. 2009;147:45-50.
22. Robin AL, Suan EP, Sjaarda RN, et al, Alcon Anecortave Acetate for IOP Research Team. Reduction of intraocular pressure with anecortave acetate in eyes with ocular steroid injection-related glaucoma. Arch Ophthalmol. 2009;127:173-178.